Does Hydrochlorothiazide Deplete Zinc? What the Research Says

Yes, hydrochlorothiazide depletes zinc through increased urinary excretion. This is a less well-known side effect compared to HCTZ's potassium and magnesium depletion, but the evidence is consistent across multiple study types. CTD's molecular database documents 690 randomized controlled trials involving 382,294 patients mapping HCTZ's effects on electrolyte and mineral metabolism, with 24 meta-analyses synthesizing the findings. PubMed indexes 3,163 articles specifically on HCTZ pharmacology. The zinc depletion is classified as moderate severity, developing gradually over months of daily use. Because HCTZ is typically prescribed as a long-term antihypertensive, even moderate daily zinc losses compound into clinically significant depletion. Zinc is a cofactor for over 300 enzymes and plays essential roles in immune defense, wound healing, protein synthesis, and DNA repair — making chronic depletion consequential well beyond the mineral itself.

The evidence for HCTZ-induced zinc depletion comes from clinical studies measuring urinary zinc excretion in hypertensive patients and from observational data linking long-term thiazide use to lower serum zinc levels. On the zinc side, CTD documents 821 randomized controlled trials across 1,273,720 patients studying zinc's biological roles, with PubMed indexing 23,900 articles on zinc metabolism. FAERS adverse event monitoring for HCTZ captures reports of impaired taste, slow wound healing, and increased infection frequency — symptoms consistent with progressive zinc insufficiency that clinicians often attribute to aging rather than medication effects. The clinical significance is amplified by the population taking HCTZ: older adults with hypertension who already face age-related declines in zinc absorption from the gut. Adding medication-driven urinary losses to declining dietary absorption creates a double hit on zinc balance that explains why hypertensive patients on thiazides show lower zinc levels than age-matched controls not on diuretics.

HCTZ depletes zinc through altered renal tubular handling tied to its primary mechanism of action. By blocking the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, HCTZ increases sodium delivery to downstream nephron segments. This shifts the electrochemical environment and impairs the reabsorption of divalent cations including zinc through transporters like ZIP and ZnT family members in the tubular epithelium. The increased urine flow rate from diuresis also physically washes out zinc that would otherwise be reabsorbed. Additionally, HCTZ-induced changes in carbonic anhydrase activity may alter the pH-dependent binding of zinc to tubular proteins, further reducing reabsorption efficiency. The zinc losses are dose-dependent and additive with HCTZ's simultaneous depletion of magnesium and potassium. Patients taking HCTZ alongside ACE inhibitors like lisinopril face compounded zinc losses because ACE is itself a zinc-dependent metalloenzyme, and ACE inhibitors independently increase urinary zinc excretion.

Test serum zinc at baseline and every 6-12 months during HCTZ therapy. Normal serum zinc ranges from 60-120 mcg/dL, with optimal levels above 80 mcg/dL. If levels decline, supplement with 15-30 mg of elemental zinc daily using zinc picolinate or zinc glycinate for best absorption. Take zinc supplements at least 2 hours apart from HCTZ to avoid absorption interference. Zinc competes with copper for absorption, so if supplementing above 30 mg daily for more than 2-3 months, add 1-2 mg of copper to prevent copper depletion. Prioritize zinc-rich foods: oysters (74 mg per 3 oz — the richest food source by far), beef (7 mg per 3 oz), pumpkin seeds (2.2 mg per ounce), and lentils (2.5 mg per cup). If you also take lisinopril or another ACE inhibitor alongside HCTZ, the combination doubles your zinc depletion risk and makes monitoring and supplementation more urgent. Discuss your full medication list with your provider to assess cumulative zinc depletion burden.